Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 25-33

  Komabayashi, Yuki ^a   Kishibe, Kan ^a   Nagato, Toshihiro ^a   Ueda, Seigo ^a   Takahara, Miki ^a   Harabuchi, Yasuaki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; LATENT MEMBRANE PROTEIN 1; MICRORNA 15A; PROTEIN MYB;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; NK T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS V-MYB; PROGNOSIS; VIRAL MATRIX PROTEINS;

EID: 84892850273     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23570     Document Type: Article

References (45)

1. Harabuchi Y, Imai S, Wakashima J, et al. Nasal T-cell lymphoma causally associated with Epstein-Barr virus: Clinicopathologic, phenotypic, and genotypic studies. Cancer 1996;77:2137-2149.
2. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-111.
3. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood 2001;97:708-713.
4. Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990;335:128-130.
5. Minarovits J, Hu L, Imai S, et al. Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. J Gen Virol 1994;75:77-84.
6. Nagato T, Kobayashi H, Kishibe K, et al. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 2005;11:8250-8257.
7. Takahara M, Kis LL, Nagy N, et al. Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 2006;119:2775-2783.
8. Moriai S, Takahara M, Ogino T, et al. Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res 2009;15:6771-6779.
9. Ishii H, Takahara M, Nagato T, et al. Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int J Cancer 2012;130:48-58.
10. Yoshino K, Kishibe K, Nagato T, et al. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27. Br J Haematol 2013;160:331-342.
11. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
12. Calin GA, Croce CM. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 2006;66:7390-7394.
13. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
14. Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009;114:3265-3275.
15. Ng SB, Yan J, Huang G, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011;118:4919-4929.
16. Paik JH, Jang JY, Jeon YK, et al. MicroRNA-146a Downregulates NFκB Activity via Targeting TRAF6 and Functions as a Tumor Suppressor Having Strong Prognostic Implications in NK/T Cell Lymphoma. Clin Cancer Res 2011;17:4761-4771.
17. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10:1419-1432.
18. Yagita M, Huang C, Umehara H, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000;14:922-930.
19. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994;8:652-658.
20. Matsuo Y, Drexler HG. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res 2003;27:935-945.
21. Epstein MA, Achong BG, Barr YM, et al. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 1966;37:547-559.
22. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 1977;19:621-626.
23. Kanemitsu N, Isobe Y, Masuda A, et al. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): Differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL. Clin Cancer Res 2012;18:2164-2172.
24. Shu GS, Lv F, Yang ZL, et al. Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Int J Clin Oncol 2012.
25. Sgambato A, Migaldi M, Faraglia B, et al. Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer Journal international du cancer 2002;97:671-678.
26. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-13949.
27. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-1277.
28. Zhao H, Kalota A, Jin S, et al. The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood 2009;113:505-516.
29. Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009;69:5553-5559.
30. Furukawa Y, Piwnica-Worms H, Ernst TJ, et al. cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science (New York, NY) 1990;250:805-808.
31. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529.
32. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov 2012;2:591-597.
33. Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2013.doi: 10.1038/leu.2013.157.
34. Li G, Miskimen KL, Wang Z, et al. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood 2010;115:1416-1424.
35. Cameron JE, Yin Q, Fewell C, et al. Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol 2008;82:1946-1958.
36. Luo W, Yan G, Li L, et al. Epstein-Barr virus latent membrane protein 1 mediates serine 25 phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKCalpha/PKCbeta pathway. Mol Carcinog 2008;47:934-946.
37. Yang J, Deng X, Deng L, et al. Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J Exp Clin Cancer Res 2004;23:495-506.
38. Cohen EE, Zhu H, Lingen MW, et al. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res 2009;69:65-74.
39. Zhang X, Chen X, Lin J, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012;31:3002-3008.
40. Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 2011;223:496-510.
41. Mao X, Onadim Z, Price EA, et al. Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement. J Invest Dermatol 2003;121:618-627.
42. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010;115:1226-1237.
43. Huang YH, Lin KH, Chen HC, et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PloS One 2012;7:e37188.
44. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-1801.
45. Gao X, Zhang R, Qu X, et al. MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk Res 2012;36:1505-1509.